Abstract:
Introduction. Since one of the main factors determining the pathogenic effect of HPV infection is local
immunodeficiency, a number of authors suggest using various cytokines and immunomodulators. Recently, peptide-based
agents have been increasingly used in routine clinical practice. Objective. To study the effect of peptide immunocorrection on
molecular and cellular factors affecting the course of grade II cervical dysplasia (CIN2) as a precancerous process and to
evaluate the effectiveness of the proposed regimen. Materials and methods. The study included 2 groups of patients aged 28 to
44 years who were colposcopically and cytologically diagnosed with grade 2 cervical dysplasia. Clinical monitoring,
determination of HPV by PCR, immunohistochemical studies of biomarkers of inflammation and proliferation, as well as
counting of T-lymphocytes in cervical mucus preparations were performed before treatment, after treatment, after 6 weeks and
after 3 months. Results. During the study of the expression level of pro-oncogenic interleukin IL-8 and anti-oncogenic IL-12, it
was established that in both observation groups after the immunotherapy, a tendency to decrease the pro-oncogenic potential of
cervical mucus was noted. Analysis of the level of expression of the cell proliferation marker Ki-67 in the clinical monitoring
groups showed that the proposed therapy schemes reduced the proliferative potential of the cervical epithelium. The number of
active cytotoxic lymphocytes in the cervical mucus in both observation groups predictably increased after the use of local
immunotherapy. The study showed that immunotherapy of cervical dysplasia with the use of peptides demonstrated
significantly better clinical results compared to the reference group. Conclusion. Taking into account the obtained research
results and the given clinical cases, peptide immunocorrection can be reasonably recommended as an immunological
component in the treatment of cervical dysplasia (ASCUS and LSIL).
